Work

P-219: Daratumumab (DARA) + lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN

Year: 2022

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)00549-3

Authors: Ajay Nooka, Jonathan Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah Holstein, Larry Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas Lin, Saad Usmani, Paul Richardson, Peter Voorhees

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4293041648

Cites:

Cited by:

Related to: 10